JP2021506824A5 - - Google Patents
Info
- Publication number
- JP2021506824A5 JP2021506824A5 JP2020532949A JP2020532949A JP2021506824A5 JP 2021506824 A5 JP2021506824 A5 JP 2021506824A5 JP 2020532949 A JP2020532949 A JP 2020532949A JP 2020532949 A JP2020532949 A JP 2020532949A JP 2021506824 A5 JP2021506824 A5 JP 2021506824A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- modified polypeptide
- polypeptide according
- domain
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023087721A JP7797441B2 (ja) | 2017-12-15 | 2023-05-29 | ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762599444P | 2017-12-15 | 2017-12-15 | |
| US62/599,444 | 2017-12-15 | ||
| PCT/US2018/066033 WO2019118974A2 (en) | 2017-12-15 | 2018-12-17 | Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023087721A Division JP7797441B2 (ja) | 2017-12-15 | 2023-05-29 | ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021506824A JP2021506824A (ja) | 2021-02-22 |
| JP2021506824A5 true JP2021506824A5 (https=) | 2022-02-07 |
| JP7494115B2 JP7494115B2 (ja) | 2024-06-03 |
Family
ID=66819031
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532949A Active JP7494115B2 (ja) | 2017-12-15 | 2018-12-17 | ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒 |
| JP2023087721A Active JP7797441B2 (ja) | 2017-12-15 | 2023-05-29 | ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023087721A Active JP7797441B2 (ja) | 2017-12-15 | 2023-05-29 | ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11491239B2 (https=) |
| EP (1) | EP3723784A4 (https=) |
| JP (2) | JP7494115B2 (https=) |
| CN (2) | CN119954917A (https=) |
| WO (1) | WO2019118974A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3723784A4 (en) * | 2017-12-15 | 2022-01-12 | The Medical College of Wisconsin, Inc. | USE OF MODIFIED CLOSTRIDIAL NEUROTOXINS AS VACCINES AND CONJUGATE VACCINE PLATFORMS |
| WO2020024002A1 (en) * | 2018-07-31 | 2020-02-06 | Snoretox Pty Ltd | Pegylated tetanus neurotoxins and treatment of hypotonia |
| US12344635B2 (en) | 2020-03-24 | 2025-07-01 | The Medical College Of Wisconsin, Inc. | COVID-19 vaccine |
| BR112022024303A2 (pt) | 2020-05-30 | 2023-01-31 | Prime Bio Inc | Composição de vacina recombinante oral/sublingual/nasal, candidatos a vacina recombinante, e método de imunização contra a covid-19 |
| WO2022083585A1 (zh) * | 2020-10-20 | 2022-04-28 | 上海瑞宙生物科技有限公司 | 一种蛋白多糖结合物及其应用 |
| CN114958887B (zh) * | 2021-02-26 | 2024-10-25 | 重庆誉颜制药有限公司 | 一种经修饰的毒素多肽的制备方法 |
| CN115192702B (zh) * | 2022-06-22 | 2025-07-15 | 上海赛伦生物技术股份有限公司 | 一种破伤风修饰性mRNA疫苗及其制备方法 |
| CN115304673B (zh) * | 2022-06-24 | 2024-10-01 | 上海赛伦生物技术股份有限公司 | 一种马抗破伤风特异性免疫球蛋白F(ab’)2的纯化方法及其应用 |
| WO2026015556A1 (en) * | 2024-07-08 | 2026-01-15 | The Medical College Of Wisconsin, Inc. | BoNT AND TeNT POLYPEPTIDE FRAGMENTS AND/OR VARIANTS, COMPOSITIONS, POLYNUCLEOTIDES, VACCINES, AND CONJUGATE VACCINE PLATFORMS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1232304C (zh) * | 1996-03-23 | 2005-12-21 | 财团法人阪大微生物病研究会 | 破伤风毒素功能性片段抗原和破伤风疫苗 |
| GB9914861D0 (en) | 1999-06-25 | 1999-08-25 | Imperial College | Tetanus toxin polypeptides |
| ATE348178T1 (de) * | 1999-08-25 | 2007-01-15 | Allergan Inc | Aktivierbare rekombinante neurotoxine |
| US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| US8853360B2 (en) * | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
| EP3723784A4 (en) * | 2017-12-15 | 2022-01-12 | The Medical College of Wisconsin, Inc. | USE OF MODIFIED CLOSTRIDIAL NEUROTOXINS AS VACCINES AND CONJUGATE VACCINE PLATFORMS |
| US12344635B2 (en) | 2020-03-24 | 2025-07-01 | The Medical College Of Wisconsin, Inc. | COVID-19 vaccine |
-
2018
- 2018-12-17 EP EP18889393.7A patent/EP3723784A4/en active Pending
- 2018-12-17 WO PCT/US2018/066033 patent/WO2019118974A2/en not_active Ceased
- 2018-12-17 CN CN202411849786.4A patent/CN119954917A/zh active Pending
- 2018-12-17 CN CN201880081008.1A patent/CN111479821B/zh active Active
- 2018-12-17 US US16/772,590 patent/US11491239B2/en active Active
- 2018-12-17 JP JP2020532949A patent/JP7494115B2/ja active Active
-
2022
- 2022-10-03 US US17/959,272 patent/US12611464B2/en active Active
-
2023
- 2023-05-29 JP JP2023087721A patent/JP7797441B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506824A5 (https=) | ||
| WO2019118974A4 (en) | Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms | |
| CN102711794B (zh) | 用于疫苗和诊断学的Dps融合蛋白 | |
| HRP20170094T1 (hr) | Imunogeni pripravak | |
| Seto et al. | Identification of a 521-kilodalton protein (Gli521) involved in force generation or force transmission for Mycoplasma mobile gliding | |
| JP2021519599A5 (https=) | ||
| FI3583120T3 (fi) | Muunneltuja transferriinireseptoria sitovia polypeptidejä | |
| CN116019906A (zh) | 新型冠状病毒免疫原性组合物、其制备方法和应用 | |
| JP2010162023A5 (https=) | ||
| JP2009540801A5 (https=) | ||
| JP2013520487A5 (https=) | ||
| Afshari et al. | In-silico design and evaluation of an epitope-based serotype-independent promising vaccine candidate for highly cross-reactive regions of pneumococcal surface protein A | |
| CN110551187A (zh) | 化学合成的h7n9禽流感病毒na蛋白胞外区抗原片段及制备方法和应用 | |
| JP7525093B2 (ja) | 改変ｈ因子結合タンパク質 | |
| JP2020509770A5 (https=) | ||
| AU2020367242B2 (en) | Influenza virus vaccines and uses thereof | |
| JP2009501012A5 (https=) | ||
| JP2006520184A5 (https=) | ||
| Yousefi et al. | B and T-Cell Epitope Prediction of the OMP25 Antigen for Developing Brucella melitensis Vaccines for Sheep. | |
| US20240084310A1 (en) | Recombinant expression vector for production of encapsulin-based vaccine and method for manufacturing the same | |
| US7255855B2 (en) | Surface expression method of peptides P5 and Anal3 using the gene encoding poly-gamma-glutamate synthetase | |
| AU2021363921A9 (en) | Fusion protein and vaccine | |
| Honma et al. | Molecular analysis of a filamentous phage (fsl) of Vibrio cholerae O139 | |
| CN118530314B (zh) | 广谱型流感疫苗抗原片段、重组益生菌及应用 | |
| Andersson et al. | Improved systems for hydrophobic tagging of recombinant immunogens for efficient iscom incorporation |